Azole Drugs Trap Cytochrome P450 EryK in Alternative Conformational States

被引:17
|
作者
Montemiglio, Linda Celeste
Gianni, Stefano
Vallone, Beatrice
Savino, Carmelinda [1 ]
机构
[1] Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy
关键词
STRUCTURAL BASIS; C-12; HYDROXYLASE; ACTIVE-SITE; P450; INHIBITION; CHEMISTRY; MECHANISM; BACTERIAL; BINDING; CYP51;
D O I
10.1021/bi101062v
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
EryK is a bacterial cytochrome P450 that catalyzes the last hydroxylation occurring during the biosynthetic pathway of erythromycin A in Streptomyces erythraeus. We report the crystal structures of EryK in complex with two widely used azole inhibitors: ketoconazole and clotrimazole. Both of these ligands use their imidazole moiety to coordinate the heme iron of P450s. Nevertheless, because of the different chemical and structural properties of their N1-substituent group, ketoconazole and clotrimazole trap EryK, respectively, in a closed and in an open conformation that resemble the two structures previously described for the ligand-free EryK. Indeed, ligands induce a distortion of the internal helix I that affects the accessibility of the binding pocket by regulating the kink of the external helix G via a network of interactions that involves helix F. The data presented thus constitute an example of how a cytochrome P450 may be selectively trapped in different conformational states by inhibitors.
引用
收藏
页码:9199 / 9206
页数:8
相关论文
共 50 条
  • [1] Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs
    Venkateswarlu, K
    Denning, DW
    Kelly, SL
    JOURNAL OF MEDICAL AND VETERINARY MYCOLOGY, 1997, 35 (01): : 19 - 25
  • [2] Mechanistic Insights into Cytochrome P450 Inactivation by Azole Drugs in <it>Acanthamoeba castellanii</it>
    Sharma, Vandna
    Shing, Brian
    Debnath, Anjan
    Podust, Larissa
    FASEB JOURNAL, 2020, 34
  • [3] Cytochrome p450 conformational diversity
    Stout, CD
    STRUCTURE, 2004, 12 (11) : 1921 - 1922
  • [4] Cytochrome P450 and anticancer drugs
    Fujita, K
    CURRENT DRUG METABOLISM, 2006, 7 (01) : 23 - 37
  • [5] Expression, purification, and crystallization of the cytochrome P450 responsible for the C12 hydroxylation of erythromycin, cytochrome P450eryK
    Woyski, D
    Cupp-Vickery, J
    FASEB JOURNAL, 1999, 13 (07): : A1345 - A1345
  • [6] Investigating the Structural Plasticity of a Cytochrome P450 THREE-DIMENSIONAL STRUCTURES OF P450 EryK AND BINDING TO ITS PHYSIOLOGICAL SUBSTRATE
    Savino, Carmelinda
    Montemiglio, Linda C.
    Sciara, Giuliano
    Miele, Adriana E.
    Kendrew, Steven G.
    Jemth, Per
    Gianni, Stefano
    Vallone, Beatrice
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (42) : 29170 - 29179
  • [7] Displaced Conformational Equilibrium in a Piezophilic Cytochrome P450
    Sineva, Elena V.
    Halpert, James R.
    Davydov, Dmitri R.
    FASEB JOURNAL, 2010, 24
  • [8] Conformational Landscape of Cytochrome P450 Reductase Interactions
    Sellner, Manuel
    Fischer, Andre
    Don, Charleen G.
    Smiesko, Martin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (03) : 1 - 14
  • [9] To Be, or Not to Be, an Inhibitor: A Comparison of Azole Interactions with and Oxidation by a Cytochrome P450 Enzyme
    Podgorski, Matthew N.
    Coleman, Tom
    Giang, Peter D.
    Wang, C. Ruth
    Bruning, John B.
    Bernhardt, Paul, V
    De Voss, James J.
    Bell, Stephen G.
    INORGANIC CHEMISTRY, 2022, 61 (01) : 236 - 245
  • [10] A study of conformational states of substrates of isoform 3A4 of cytochrome P450
    Grishina M.A.
    Potemkin V.A.
    Pogrebnoi A.A.
    Ivshina N.N.
    Biophysics, 2008, 53 (5) : 355 - 360